Ionis Pharmaceuticals (IONS) Leerink Global Healthcare Conference 2026 summary

Key product launches and market evolution

• TRYNGOLZA achieved priority review and strong phase III data, setting up a transformative 2026 with multiple game-changing events.

• FCS launch generated $108 million in 2025, exceeding expectations and showing strong patient access and payer engagement.

• SHTG launch targets a broader population (over 3 million in the US), with initial focus on high-risk patients and a June 30 PDUFA date.

• Despite new competition, TRYNGOLZA maintains strong adherence and persistence, though faces pricing pressure.

• Peak US sales projections for TRYNGOLZA and SHTG increased to over $2 billion based on HCP demand and payer research.

Pricing, competition, and payer strategy

• Facing pricing pressure in FCS due to a lower-priced competitor, but managing negotiations effectively.

• SHTG pricing will be announced at launch, with efforts to maximize value while ensuring broad patient access.

• First-mover advantage and robust clinical data are expected to drive early SHTG adoption, especially among high-risk patients.

• Once-monthly auto-injector administration is seen as highly convenient, with no significant advantage for less frequent dosing.

Clinical data and safety insights

• TRYNGOLZA phase III data showed 85% reduction in acute pancreatitis and 72% reduction in triglycerides.

• Small, dose-dependent increases in liver fat observed, but long-term data show return to baseline with no clinical toxicity.

• Upcoming data on hepatic fat fraction will be presented later in the year.